Mesenchymal stem cells (multipotent stromal cells; MSCs) have been under investigation for
the treatment of diverse diseases, with many promising outcomes achieved in animal …

Mesenchymal stem cells (MSCs) are one of a few stem cell types to be applied in clinical
practice as therapeutic agents for immunomodulation and ischemic tissue repair. In addition …

Introduction Administration of bone marrow mesenchymal stem cells (MSCs) or secreted
microvesicles improves recovery from acute kidney injury (AKI). However, the potential roles …

Reno‐protective strategies are needed to improve renal outcomes in patients with
atherosclerotic renal artery stenosis (ARAS). Adipose tissue‐derived mesenchymal stem …

Critically ill patients often suffer from multiple organ failures involving lung, kidney, liver, or
brain. Genomic, proteomic, and metabolomic approaches highlight common injury …

Acute kidney injury (AKI) is defined as a pathological condition in which the glomerular
filtration rate decreases rapidly over a short period of time, resulting in changes in the …

Renal failure has a high prevalence and is becoming a public health problem worldwide.
However, the renal replacement therapies such as dialysis are not yet satisfactory for its …

Mesenchymal stem cells (MSC) are a population of tissue‐resident adult progenitor cells
that were originally identified in bone marrow, but have now been identified in many organs …

Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads
to loss of kidney function with limited therapeutic options. Here we describe results of Phase …

Ischemia-reperfusion injury (IRI) plays a significant role in the pathogenesis of acute kidney
injury (AKI). The complicated interaction between injured tubular cells, activated endothelial …